Despite the European Medicines Agency according GMP Annex 1 a high priority work item, it is still unclear when a revised annex will be released and whether a final version will be implemented right away or go out again for public comment.
So asserted Jean-Francois Duliere, a GMP consultant who is chair of the International Society for Pharmaceutical Engineering's France affiliate, and...





